EMERSON PERIN to Transplantation, Autologous
This is a "connection" page, showing publications EMERSON PERIN has written about Transplantation, Autologous.
Connection Strength
1.167
-
The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):169-177.
Score: 0.126
-
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. Am Heart J. 2014 Nov; 168(5):667-73.
Score: 0.109
-
Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J. 2014 Jul; 168(1):88-95.e2.
Score: 0.107
-
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012 Apr 25; 307(16):1717-26.
Score: 0.093
-
Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J. 2012 Mar; 163(3):415-21, 421.e1.
Score: 0.092
-
CD34+ autologous human stem cells in treating refractory angina. Circ Res. 2011 Aug 05; 109(4):351-2.
Score: 0.089
-
A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv. 2011 Dec 01; 78(7):1060-7.
Score: 0.087
-
Autologous cell-based therapy for ischemic heart disease: clinical evidence, proposed mechanisms of action, and current limitations. Catheter Cardiovasc Interv. 2009 Feb 15; 73(3):281-8.
Score: 0.075
-
[Sustained improvement in symptoms and exercise capacity up to six months after autologous transendocardial transplantation of bone marrow mononuclear cells in patients with severe ischemic heart disease]. Arq Bras Cardiol. 2005 May; 84(5):360-6.
Score: 0.058
-
Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004 Sep 14; 110(11 Suppl 1):II213-8.
Score: 0.055
-
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003 May 13; 107(18):2294-302.
Score: 0.050
-
Autologous vein-coated stent for exclusion of a coronary artery aneurysm: case report with postimplantation intravascular ultrasound characteristics. Tex Heart Inst J. 1999; 26(3):223-5.
Score: 0.037
-
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure). Circ Res. 2018 06 08; 122(12):1703-1715.
Score: 0.035
-
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. Am Heart J. 2018 07; 201:54-62.
Score: 0.035
-
Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. Stem Cells Transl Med. 2016 Feb; 5(2):186-91.
Score: 0.030
-
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011 Nov 16; 306(19):2110-9.
Score: 0.023
-
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. Am Heart J. 2010 Aug; 160(2):215-23.
Score: 0.021
-
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010; 37(4):412-20.
Score: 0.020
-
Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findings. Circulation. 2005 Jul 26; 112(4):521-6.
Score: 0.015
-
Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation. Tex Heart Inst J. 2004; 31(3):214-9.
Score: 0.013